The
bioburden testing market is witnessing growth due to factors such as growth in
the medical devices, pharmaceutical, and biotechnology industries; rising
safety concerns related to food and beverage products; and the increasing
number of product recalls due to microbial contamination are expected to drive
the growth of this market during the forecast period.
Bioburden Testing Market Dynamics: Impact Analysis
1. Geographical Snapshot of the Bioburden Testing Market
2. Growth Opportunities in Emerging Economies
3. Growth in the Medical Devices, Pharmaceutical, and Biotechnology Sector
4. Safety Concerns Related to Food and Beverage Products
5. Increasing Food Imports Into the US
The bioburden testing market to grow from USD 1.10 billion by 2023 from USD 0.61 billion
in 2018, at a Compound Annual Growth Rate (CAGR) of 12.4%
Key Questions Addressed in The Report:
1. Who are the top 10 players operating in the global Bioburden
Testing market?
2. What are the drivers, restraints, opportunities, and challenges in the
Bioburden Testing Industry?
3. What are the opportunities
for stakeholders and provide details of the competitive landscape for key
players?
4. What will be growth of Bioburden Testing in North America, Europe, Asia
Pacific, Latin America, and the Middle East and Africa?
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17983056
Bioburden Testing Application: Raw Materials Testing
Based
on the application, the bioburden testing market is segmented into raw
materials testing, medical devices testing, in-process material testing,
sterilization validation testing, and equipment cleaning validation. In 2018,
the raw materials testing segment is expected to grow at the highest CAGR
during the forecast period. Growth in this segment is likely to be driven by
the rising quality standards to ensure safety of finished products.
Products of Bioburden Testing: Consumables Segment
Based on product, the bioburden testing market is segmented consumables and
instruments. Consumables segment further segmented into culture media, reagents
and kits, and other consumables. Instruments segment further categorised as
automated microbial identification system, PCR, microscope, and other
instruments. In 2018, the consumables segment is expected to account for the
largest share of the bioburden testing market. The large share of this segment
majorly attributed to the requirement of repeat purchase of kits and reagents,
unlike instruments which are considered as a one-time investment.
Regional Growth Analysis: North America and Europe to Dominate The Industry:
The market is dominated by North America, followed by Europe, Asia, and
RoW. North America is expected to continue to dominate this market in the
forecast period. The large size of the North American biotechnology industry
will aid in the growth of the bioburden testing market in this region. However,
Asia is expected to grow at the highest CAGR during the forecast period. Strong
investments and rapid growth in the pharmaceutical and biotechnology industries
will drive the growth of the bioburden testing market in this region.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=17983056
Key Players:
The bioburden testing
market is competitive in nature, with several big as well as emerging players.
Prominent players in this market include Charles River (US), Merck KGaA
(Germany), SGS SA (Switzerland), WuXi AppTec (China), Becton, Dickinson, and
Company (US), NAMSA (US), Nelson Laboratories, LLC (US), Thermo Fisher
Scientific, Inc. (US), Biomérieux SA (France), and Pacific BioLlabs (US)
